Literature DB >> 2275226

Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS.

D P Nicolau1, T E West.   

Abstract

An increasing number of AIDS patients have been noted to suffer severe recurrent aphthous stomatitis (RAS), a condition often associated with high morbidity that remains unresponsive to conventional therapeutic interventions. In two cases thalidomide was administered to successfully treat AIDS patients with RAS. Both patients experienced complete abatement of pain shortly after therapy was initiated. Ulcerations that were present for months resolved after three or four weeks of thalidomide therapy without any adverse effects. Thalidomide appears to be an effective agent for the treatment of severe RAS unresponsive to traditional therapies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2275226     DOI: 10.1177/106002809002401105

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  4 in total

1.  [Not Available].

Authors:  K Kurz-Müller; M Zenz
Journal:  Schmerz       Date:  1992-03       Impact factor: 1.107

2.  Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals.

Authors:  S M Naum; P J Molloy; R J Kania; J McGarr; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

Review 3.  Thalidomide: rationale for renewed use in immunological disorders.

Authors:  U Schuler; G Ehninger
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

4.  Cloning, expression and characterization of biologically active feline tumour necrosis factor-alpha.

Authors:  E Rimstad; G H Reubel; G A Dean; J Higgins; N C Pedersen
Journal:  Vet Immunol Immunopathol       Date:  1995-04       Impact factor: 2.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.